Biotech Daily

Tuesday September 1, 2026

Daily news on ASX-listed biotechnology companies

*** AUGUST BDI-40 UP 9%, ASX200 UP 3%, BIG CAPS UP 22%, NBI UP 10%**

*** TODAY: ASX, BIOTECH DOWN: CURVEBEAM UP 11%; PARADIGM DOWN 9%**

*** CSL, US AGREE ON LOWER COST MEDICINES, MANUFACTURE**

*** REDHILL SELLS TALICIA (HELICONDA) TO APOTEX FOR UP-TO $74m**

*** EPSILON H1 REVENUE UP 123% TO $8m; LOSS DOWN 65% TO $726k**

*** CANN REVENUE DOWN 24% TO $9m; $22m LOSS TO $20m PROFIT**

*** CONNEQT REVENUE UP 77% TO $6m; LOSS DOWN 40% TO $11m**

*** EMYRIA REVENUE UP 191% TO $4m; LOSS UP 95% TO $6m**

*** PERCHERON ‘COMMITMENTS’ FOR $2.3m PLACEMENT**

*** CURVEBEAM $606k SHARE PLAN; $394k SHORTFALL; TOTAL $5.6m**

*** ACTINOGEN: FORREST CAPITAL UNDERWRITES $4.8m OPTIONS**

*** VICTORIA, RMIT $1m FOR GONDA’S GONGLOBAL IVF TREATMENT**

*** MEMPHASYS SIGNS $853k NORDIC FELIX CONTRACT**

*** LTR AUSTRALIAN KYZATREX ORAL TESTOSTERONE**

*** RACURA OPENS SOUTH KOREA PHASE I RC220 TUMOR TRIAL**

*** OPTISCAN BEGINS US INVUE, INFORM HEAD, NECK CANCER STUDY**

*** CARTHERICS, ZUCKER TISSUE FACTOR CAR-NK FOR CANCERS**

*** TRUSCREEN AGM 24.7% OPPOSE DIRECTOR FEE POOL HIKE**

*** CURVEBEAM M-D GREG BROWN TAKES 7%**

*** TELIX DIRECTOR DAVID GILL REPLACES CHAIR DR MARK NELSON**

*** ECHO IQ APPOINTS SCOTT WILKIN DIRECTOR**

*** PERCHERON APPOINTS CFO, CO SEC DEBORAH AMBROSINI DIRECTOR**

*** ALISON HALE REPLACES ADHERIS CFO SEAN SLATTERY**

MARKET REPORT

The Australian stock market fell 0.1 percent on Tuesday September 1, 2026, with the ASX200 down 9.3 points to 9,066.7 points. Thirteen of the Biotech Daily Top 40 companies were up, 15 fell, 11 traded unchanged and one was untraded.

Curvebeam was the best, up 0.2 cents or 11.1 percent to 2.0 cents, with 82,774 shares traded. Immutep climbed 6.25 percent; Botanix and Racura were up five percent or more; Artrya, Dimerix, EBR and Prescient improved three percent or more; Clarity, Clinuvel and Compumedics rose two percent or more; Emvision was up 1.2 percent; with Cochlear, CSL, Neuren and Resmed up by less than one percent.

Paradigm led the falls, down 2.0 cents or 8.9 percent to 20.5 cents, with 4.9 million shares traded. Cyclopharm and Micro-X lost more than seven percent; Actinogen and Lumos fell more than four percent; Nova Eye and Orthocell were down more than three percent; Imricor, Medical Developments, Nanosonics and Saluda shed more than two percent; Pro Medicus was down 1.7 percent; with Aroa, Avita, Mesoblast and Telix down by less than one percent.

BIOTECH DAILY TOP 40 INDEX (BDI-40)

The wattle is in flower and the orchids are beginning to bloom. Spring has sprung in Melbourne and all indices were up for the last month of Winter.

The Biotech Daily Top 40 Index (BDI-40) climbed 9.25 percent in August to a collective market capitalization of $20,640 million, the benchmark ASX200 was up 3.15 percent to 9,076 points, and the four Big Caps of Cochlear, CSL, Pro Medicus and Resmed, which are not included in the BDI-40, jumped a collective 21.9 percent to $157,325 million, but 27.0 percent below the $215,588 million, a year ago. The Nasdaq Biotechnology Index was up 10.4 percent in August and 52.3 percent for the year to August 31, 2026.

CSL led the Big Caps, recovering a further $20,900 million or 34.1 percent to $82,167 million, Pro Medicus climbed 11.6 percent to $18,741 million, Resmed was up 10.9 percent to $47,659 million, with Cochlear up 9.6 percent to $8,758 million.

Thirty-one of the BDI-40 companies were up in August, with 10 up by more than 10 percent; seven fell, of which four fell by more than 10 percent. Two were unchanged.

Avita was the percentage best in August, up $231 million or 115.5 percent to $431 million, but it was Telix that again added the most to the index, up $438 million or 9.2 percent to $5,219 million. From a much lower base, Paradigm was up 39.8 percent to $137 million, followed by Curvebeam (22.2%), Polynovo (18.8%), Mesoblast (15.7%), Dimerix (14.3%), Compumedics (13.3%), Neuren (12.95%), Impedimed (12.5%) and Alcidion (10.2%).

From a lower base, Prescient led the few falls, down $20 million or 22.5 percent to $69 million, Imugene (16.7%), Clinuvel down $664 million or 13.7 percent to $404 million following its news that it was also going to the Nasdaq in search of better valuations and Nanosonics was down 11.9 percent.

Outside the BDI-40, Echo IQ re-joined the billion-dollar club along with Anteris, while PYC joined the two-billion-dollar club.

Vitrafy was at its highest end-of-month valuation, having hit $354 million in mid-August, but easing to $293 million last night. Cogstate and BLS (formerly Bioxyne) were at their year's best.

The 11 companies in Cannabis & Psychedelics Corner climbed 15.8 percent for the month – up 64.5 percent for the 12 months to August 31, 2026 - led by BLS up $58 million in the month or 31.2 percent to $244 million, followed by Avecho up 21.9 percent to $89 million.

On the Nasdaq, Eyepoint (formerly Psivida) tumbled $933 million or 63.9 percent to $527 million on news that the "primary endpoint [was] not achieved" in its 400-patient, 'Lugano' phase III trial of Duravyu for wet age-related macular degeneration (AMD). Protagonist continued its climb, more than doubling for the year to $13,343 million, Redhill jumped 33.3 percent in August from a very low base and Incannex was up 12 percent.

BDI-40 v ASX200 Jun 30, 2006 to Aug 31, 2026- Adjusted



5-Year Big Caps $m (COH, CSL, PME, RMD) To Aug 31, 2026



CSL

CSL says it has agreed with the US Government to lower the cost of medicines in the US and plans to expand its US plasma production capacity.

Earlier this year, CSL said it began construction on a $US1.5 billion ($A2.1 billion) expansion of its plasma-derived therapies manufacturing facility in Kankakee, Illinois (BD: Mar 10, 2026).

Today, the company said it had an agreement with the US Department of Health and Human Services to “provide the US Medicaid program with access to CSL medicines at prices comparable to those available in other developed countries”.

CSL said it had agreed “to similarly price any newly launched therapies for all payers in the US [and had] … signed an on-shoring agreement with the US Department of Commerce reflecting the company’s plans to expand its manufacturing presence in Kankakee, Illinois”.

The company said that the $US1.5 billion expansion would increase its capacity to produce plasma-derived therapies and reinforced its “commitment to advancing manufacturing and economic growth in the US”.

CSL said it did not expect “any material financial impact in 2026-’27 from these agreements, which provide it with greater certainty regarding exposure to US drug pricing and certain Section 232 tariffs”.

CSL was up 74 cents or 0.4 percent to $172.31 with 1.3 million shares traded.

REDHILL BIOPHARMA

Israel’s Redhill says Apotex will pay $US18 million ($A25.1 million) upfront and up-to $US35 million ($A48.8 million) more in potential net sales milestone payments

In 2025, Redhill said it had a $US4 million ($A6.1 million) partnership with Cumberland Pharmaceuticals for a 30 percent ownership in its Talicia business (BD: Oct 21, 2025).

In 2019, Redhill said the US Food and Drug Administration approved Talicia delayed-release capsules for Helicobacter pylori infection (BD: Nov 5, 2019).

In 2010, Redhill bought Myoconda (RHB-104), Heliconda (RHB-105, now Talicia) and Picoconda (RHB-106) from Sydney's Giaconda (BD: Aug 17, 2010).

Today, the company said the deal was “a major step in [its] strategic roadmap to fundamentally reposition [its] commercial business toward new and larger product opportunities, revenue growth and an accelerated path toward operational profitability”.

Redhill said that the agreement “realizes substantial value from [its] 70 percent stake in Talicia, currently held within a shared ownership and economic structure, while immediately creating a stronger liquidity position and fully funding the next major steps in Redhill’s transformational commercial expansion”.

Redhill chief executive officer Dror Ben-Asher said the company was “confident that given its proven capabilities, Apotex is the right home to grow Talicia globally”.

“This transaction, which unlocks the resources needed to scale Redhill’s existing gastro-intestinal commercial franchise into a stronger and larger one, including new, high-value, FDA-approved product opportunities intended to drive sustained growth and accelerate our path toward operational profitability,” Mr Ben-Asher said.

The company said that Apotex had acquired Cumberland Pharmaceuticals including its 30 percent ownership of Talicia.

Redhill said that it was advised by Morningstar Law Group and Greenberg Traurig LLP on this transaction.

On the Nasdaq, Redhill was up 0.239 US cents or 36.16 percent to 0.9 US cents (12.6 Australian cents) with 102.9 million shares traded.

EPSILON HEALTHCARE

Epsilon says revenue for the six months to June 30, 2026 was up 123.0 percent to $7,585,957, with net loss after tax down 64.9 percent to $725,972.
Epsilon said revenue was from its contract development and manufacturing services for active pharmaceutical ingredients including marijuana as well as telehealth, pharmacy and clinic services.
The company said the increased revenue reflected initiatives to establish new clients "while rebuilding, strengthening and consolidating relationships with existing clients".
Epsilon said its reduced loss related to improvements to operating cash flows supported by removing $1.2 million of costs incurred in the prior year, including external accounting, voluntary administration and legal expenses".
The company said diluted loss per share fell 68.3 percent to 0.19 cents, while net tangible assets per share was up 96 percent to 0.98 cents.
Epsilon said that it had cash and cash equivalents of $1,285,937 at June 30, 2026 compared to $3,401,788 at June 30, 2025.
Epsilon was up 0.3 cents or 14.3 percent to 2.4 cents.

CANN GROUP

Cann says revenue for the year to June 30, 2026 fell 23.9 percent to $8,600,000, with last year's $22,345,000 net loss after tax turned to a $20,304,000 profit.
Cann said revenue was from sales of its marijuana flower, oil and vaporizer products, with the decrease reflecting "continued pricing pressure in the domestic dried flower market and the company's decision to prioritize margin and cash conversion over volume in low-priced bulk channels".
The company said its profit included a gain on debt forgiveness of $55.3 million.
Last year, Cann said it had settled its $70 million loan with National Australia Bank (NAB) through the payment of $15.3 million (BD: Dec 15, 2025).
Today, the company said it had diluted earnings per share of 1.6 cents compared to a diluted loss per share of 4.23 cents in the prior year, with last year's net tangible assets per share of negative 0.44 cents turned to a positive 1.75 cents.
Cann said it had cash and cash equivalents of $490,000 at June 30, 2026 compared to $10,000 at June 30, 2025.
Cann was unchanged at 0.4 cents with 1.3 million shares traded.

CONNEQT HEALTH

Conneqt says revenue for the year to June 30, 2026 was up 77.3 percent to $6,295,285, with net loss after tax down 40.3 percent to $10,857,967.
Conneqt said revenue was "driven primarily by Conneqt Pulse sales as the consumer business expanded through 2025-'26", with research, clinical and pharmaceutical activities contributing to its revenue base.
The company said its reduced loss reflected "a reduction in total expenses following the implementation of the cost reduction initiatives in late 2024-'25 and the non-recurrence of the $4,722,153 fair value loss on investments recognized in 2024-'25".
Conneqt said diluted loss per share fell 64.7 percent to 1.8 cents, with last year's positive net tangible assets per share of 0.02 cents turned to a negative 0.06 cents.
The company said it had cash and cash equivalents of $2,566,332 at June 30, 2026 compared to $2,433,097 at June 30, 2025.
Conneqt was up 0.2 cents or 14.3 percent to 1.6 cents with 2.6 million shares traded.

EMYRIA

Emyria says revenue for the year to June 30, 2026 was up 190.6 percent to $4,053,475, with net loss after tax up 94.55 percent to $6,114,401.
Emyria said its increased revenue was driven by the expansion of its Empax clinic network for psychedelic-assisted therapy including 3,4-methylene-dioxy-meth-amphetamine (MDMA) in Australia and the start of insurer-funded treatments.
The company said its increased loss reflected investment in its "national expansion infrastructure, and clinical workforce scaling across multiple states", with costs expected to be moderate as the network scales and operational leverage improves.
Emyria said diluted loss per share fell 18.6 percent to 0.83 cents, with tangible assets per share rose 62.5 percent to 0.91 cents; and it had cash and cash equivalents of $7,290,015 at June 30, 2026 compared to $3,570,045 at June 30, 2025.
Emyria was up 0.1 cents or 2.2 percent to 4.6 cents.

PERCHERON THERAPEUTICS

Percheron says it has "firm commitments" to raise $2.3 million at 0.5 cents a share in a placement, with one option for every two shares issue.
Percheron said the issue price was an 8.9 percent premium to the 15-day volume weighted average price; and the options were exercisable at one cent each by April 15, 2028 and subject to shareholder approval.
The company said the funds would be used for costs associated with its Vanderbilt Health study of HMBD-002 in acute myeloid leukaemia and general working capital.
Last week, the company said with Vanderbilt Health it would conduct an investigator-sponsored 38-patient trial of HMBD-002 in acute myeloid leukaemia and myelodysplastic syndrome (BD: Aug 28, 2026).
Today, Percheron said subject to shareholder approval Dr Michael Baker had agreed to take up $110,000 of the placement.
The company said Blue Ocean Equities and Cygnet Capital were joint lead managers.
Percheron was unchanged at 0.5 cents with 21.4 million shares traded.

CURVEBEAM A.I.

Curvebeam says it has raised $606,150 at 1.8 cents a share in a share purchase plan, leaving a $393,850 shortfall and taking the total raised to $5,606,150.
In July, Curvebeam said it raised $5 million at 2.0 cents a share in a non-underwritten placement, with a $1 million share plan at 1.8 cents a share to follow (BD: Jul 8, 2026).
Today, the company said it reserved the right to place any shortfall shares.
Curvebeam was up 0.2 cents or 11.1 percent to two cents.

ACTINOGEN MEDICAL

Actinogen says shareholder Forrest Capital will underwrite $4,771,337 in two tranches of unlisted options expiring on September 11 and 15, 2026.
Actinogen said on completion of the underwriting it would receive the full value of the unexercised underwritten options and did "not need to contemplate placement of any shortfall that may arise after September 11 and 15, 2026 in respect of those options".
The company said it expected to issue shares on exercise of the underwritten options to Forrest Capital or its nominees on September 23, 2026.
Actinogen fell 0.2 cents or 4.65 percent to 4.1 cents with 6.2 million shares traded.

VICTORIA, ROYAL MELBOURNE INSTITUTE OF TECHNOLOGY
GONGLOBAL PTY LTD

The Victoria Government says that with the Royal Melbourne Institute of Technology it will provide $1 million for “needle-free” in-vitro fertilization (IVF) treatment.
The Minister for Economic Development Anthony Carbines said that Innovation Victoria and RMIT would each invest $500,000 for the Melbourne-based Gonglobal to develop its Ovulair inhaled in-vitro fertilization drug delivery system.
The State Government said that IVF was “physically and emotionally demanding, requiring many patients to endure hundreds of self-administered injections across multiple treatment cycles”.
The Government said that Australia had one of the world's highest rates of IVF use, with more than 100,000 cycles performed each year.
The Victoria Government media release said that Gonglobal was co-founded by former Acrux chief executive officer and Respidex founder Dr Igor Gonda and his daughter Ellen “after her experience undergoing IVF left her feeling like ‘a human pin cushion’, inspiring them to develop a needle-free alternative”.
Ms Gonda told Biotech Daily that the five main drugs, including proteins and peptides, used in IVF treatment were: follicle-stimulating hormone (FSH); luteinizing hormone (LH); human chorionic gonadotropin (hCG); gonadotropin-releasing hormone (GnRH) agonists; and gonadotropin-releasing hormone (GnRH) antagonists.
Innovation Victoria chief executive officer Rod Bristow said that Gonglobal was “a great example of how the right support at the right time can help a ground-breaking idea become not just a globally competitive business, but one that has substantial positive impact”.
RMIT deputy vice-chancellor of research and innovation Prof Calum Drummond said that “transformative research doesn’t happen in isolation – it happens when universities, industry and government bring their complementary strengths together”.
Gonglobal is a private company.

MEMPHASYS

Memphasys says it has a EUR526,500 ($A852,600), three-year contract for its Felix sperm separation system in Denmark, Sweden, Norway, Finland and Iceland.
Memphasys said the contract with Copenhagen, Denmark’s Novivitae ApS for the sale and commercialization of its Felix system for in-vitro fertilization included an initial order valued at EUR20,625 ($A33,411), plus three Felix systems.
The company said the contract expanded European commercialization of Felix to nine countries, with existing commercial arrangements in Italy, the UK, Türkiye and Poland.
Memphasys said near-term activity would “focus on supply of the initial order, distributor training, market development planning, clinic engagement and product demonstrations during the three-month evaluation period”.
The company said three-monthly minimum purchase commitments would commence following that period.
Memphasys director Marjan Mikel said the agreement was “another important step in expanding the European commercial footprint for Felix”.
“With the Nordic states added to Italy, the UK, Turkey and Poland, we now have commercial arrangements across nine European countries,” Mr Mikel said.
“Novivitae’s hands-on approach to introducing new technologies and driving clinic adoption makes it an ideal partner for Felix,” Mr Mikel said.
Memphasys was unchanged at 0.5 cents with 9.5 million shares traded.

LTR PHARMA

LTR says it will conduct a pilot program of the Raleigh, North Carolina-based Marius Pharmaceuticals' Kyzatrex oral testosterone in Australia.
LTR said the US Food and Drug Administration-approved Kyzatrex facilitated lymphatic absorption, reducing the first-pass hepatic metabolism associated with earlier oral testosterone therapies and was supported by clinical data showing its ability to restore testosterone levels in men.
The company said Kyzatrex was "a complementary opportunity for LTR to broaden its Australian men's health portfolio".
LTR said the agreement opened an initial, exclusive, six-month pilot commercialization phase in Australia, "supported by an inventory commitment sized to establish prescriber demand and operational processes".
The company said it would retain exclusivity in Australia while the parties evaluated physician adoption, patient demand and the feasibility a potential Australian Therapeutic Goods Administration registration.
LTR said following evaluation it had a right to negotiate an exclusive licence for Kyzatrex in Australia, with initial patient access through a special access scheme.
The company said the agreement was not expected to be material and it was being pursued with its core erectile dysfunction programs, including preparations for the US commercial launch of Roxus and planning for the pivotal Spontan phase III study.
LTR executive chair Lee Rodne said Kyzatrex was "a complementary opportunity to broaden our men's health portfolio by leveraging the clinical networks, telehealth channels and commercial infrastructure we have already established through Spontan".
LTR fell 1.5 cents or three percent to 49 cents.

RACURA ONCOLOGY (FORMERLY RACE ONCOLOGY)

Racura says it has opened its phase I trial of RC220 with doxorubicin for solid tumors at Ewha Womans (sic) University Seoul Hospital, its first clinical site in South Korea.
Last year, the then Race said it dosed the first patient in its 53-patient, phase I trial of RC220 bisantrene with doxorubicin for advanced solid tumors (BD: May 1, 2025).
Today, the company said pre-screening of patients had begun, with treatment of the first patient expected soon, subject to the availability of an open treatment slot.
Racura said the second and third sites, the Severance Hospital and the Samsung Medical Centre, respectively, were expected to be activated and open for patient enrolment from September 4 and 8, 2026, respectively.
The company said the final South Korean site, Asan Medical Center, had all regulatory and governance approvals, with site activation subject to signing the study contract.
Racura said activation of the trial sites in South Korea were "protracted by the protocol changes required to support the blood-based biomarker of cardio-protection".
The company said the changes required resubmission of the modified trial protocol to the Republic of Korea Ministry of Food and Drug Safety for approval and to each trial site for independent institutional review board ethics and governance approvals.
Racura managing-director Dr Daniel Tillett said that activating the "trial sites in Korea is an important milestone for Racura".
"We appreciate the dedication and enthusiasm of these world-class investigators and clinical teams participating in this trial," Dr Tillett said.
"We look forward to enrolling and treating the first patient with RC220 in Korea in the near future," Dr Tillett said.
Racura was up 11 cents or 5.2 percent to $2.24.

OPTISCAN IMAGING

Optiscan says it has begun a 35-patient, US head and neck cancer resection imaging study of its Invue and Inform microscopes with Rochester, Minnesota's Mayo Clinic.
In 2024, Optiscan said it had released its Invue microscope for providing "real-time, digital pathology access" to surgeons during surgery, and that the device could be used in cancer diagnosis and treatment (BD: Jun 4, Jul 15, 2024).
Last year, the company said Inform was a medical imaging device, for laboratory medicine, pathology practices, point-of-care and digital pathology (BD: Feb 19, 2025).
Today, Optiscan said the study would assess the effectiveness of its technology in an additional cancer type and surgical setting and was a key step in the company's efforts to expand the addressable markets for its platforms.
The company said the study would assess the performance of its devices during tumor resection surgical procedures using its Invue in-vivo and Inform ex-vivo digital pathology imaging devices to support US Food and Drug Administration filings.
Optiscan managing-director Prof Camile Farah said the study was "another great opportunity for our technology to be evaluated in an increased number of surgical settings where achieving complete tumor removal is critical".
"Through this study, we're seeking to better understand how real-time imaging can support surgical decision-making and help address an important unmet clinical need," Prof Farah said. "If the study demonstrates the potential role of real-time imaging during head and neck cancer surgery, it could further demonstrate the tangible impact Invue and Inform may have in the treatment of a wide range of cancer types".
Optiscan was unchanged at 15 cents.

CARTHERICS PTY LTD

Cartherics says with the Zucker Institute it will research its stem cell-derived CAR-NK platform with an anti-tissue factor antibody for cancer and endometriosis.
Cartherics said the Zucker Institute was the commercialization arm of Charleston's Medical University of South Carolina.
The company said it would evaluate the anti-tissue factor antibody technology in its tissue factor-targeting induced pluripotent stem cell (IPSC)-derived chimeric antigen receptor natural killer (CAR-NK) cell therapies for solid tumors.
Cartherics said tissue factor was a coagulation factor expressed in many solid tumors and had a critical role in tumor progression, angiogenesis, invasion and metastasis.
Cartherics is a private company.

TRUSCREEN GROUP

Truscreen says its annual general meeting has passed all resolutions but with up-to 24.71 percent against the 50 percent increase to the director fee pool.
Last month, Truscreen said investors would vote to increase the director fee pool by 50 percent from $NZ300,000 ($A250,000) to $NZ450,000 ($A375,000) (BD: Aug 6, 2026).
Today, the company said the increase in directors' fees was opposed by 54,702,083 votes (24.71%) with 166,674,244 votes (75.29%) in favor; with the remaining resolutions passed by more than 98.62 percent of the meeting.
According to its most recent notice, Truscreen had 1,006,790,307 shares on issue, meaning the votes against the fee pool increase was 5.43 percent of the company, sufficient to requisition extraordinary general meetings.
Truscreen was unchanged at 1.2 cents with 2.7 million shares traded.

CURVEBEAM A.I.

Curvebeam managing-director Greg Brown says he has increased his substantial shareholding from 19,346,698 shares (4.96%) to 34,474,098 shares (6.87%).
The Brisbane-based Mr Brown said that on August 14 he acquired 127,400 shares through the conversion of share rights at 18 cents each and on August 28, 2026 subscribed for 15,000,000 shares in a placement at two cents a share (see above).

TELIX PHARMACEUTICALS

Telix says it has appointed director David Gill as its chair, effective immediately, replacing interim chair Dr Mark Nelson who will continue as a non-executive director.
Earlier this year, Telix said it had appointed Mr Gill as a non-executive director and was expected to be replace Dr Nelson as chair "in due course" (BD: Apr 2, 2026).
Telix fell nine cents or 0.6 percent to $15.27 with 1.9 million shares traded.

ECHO IQ

Echo IQ says it has appointed Scott Wilkin as a non-executive director, effective from September 1, 2026.
Echo IQ said Mr Wilkin had 35 years' investment and healthcare experience and had been co-head of equity at UBS Asset Management, managing-director of Medical Technology Institutional Research at SG Cowen Securities and a director at UBS Warburg.
The company said Mr Wilkin held a Bachelor of Arts from the Brunswick, Maine-based Bowdoin College and a Master of Business Administration from the Cambridge, Massachusetts-based Harvard Business School.
Echo IQ fell 10 cents or 7.1 percent to $1.315 with 4.3 million shares traded.

PERCHERON THERAPEUTICS

Percheron says it has appointed chief financial officer and company secretary Deborah Ambrosini as a director, effective from September 1, 2026.
Percheron said the appointment was an interim transitional arrangement intended to ensure it maintained a sufficient board through the chief executive officer transition.
Last month, the company said Dr Baker would replace Dr James Garner as managing-director and chief executive officer, effective from October 5, 2026, (BD: Aug 10, 2026).
Percheron said it was expected Ms Amrbosini would "retire from the board upon the appointment of Dr Baker on October 5, 2026".
The company said Ms Ambrosini had worked for Cortical Dynamics, Acrux and Cann Group and would not be paid any additional renumeration in respect to her appointment to the board.

ADHERIS HEALTH

Adheris says Alison Hale will replace chief financial officer Sean Slattery, effective from September 1, 2026.
Adheris said Ms Hale had been an auditor at Deloitte and had worked for Linde Group and Elgas Limited.
According to her Linkedin page, Ms Hale held a Bachelor of Commerce from Sydney's Macquarie University.
Adheris was unchanged at 1.4 cents.

BIOTECH DAILY TOP 40 WITH MARKET CAPITALIZATION AT AUG 31, 2026

Company $Am	Aug 31, 2025	Jul 31, 2026	Aug 31, 2026
Cochlear	19,633	7,992	8,758
CSL	102,992	61,267	82,167
Pro Medicus	31,353	16,788	18,741
Resmed	61,610	42,969	47,659
BDI-20			
4D Medical	265	1,925	2,052
Aroa	224	197	192
Avita	179	200	431
Clarity	1,183	783	851
Clinuvel	628	468	404
Compumedics	53	45	51
Cyclopharm	109	75	69
Dimerix	270	147	168
EBR Systems	573	218	232
Immutep	360	68	71
Imricor	450	667	697
Medical Developments	66	52	52
Mesoblast	3,098	2,649	3,065
Nanosonics	1,369	936	825
Neuren	2,462	2,216	2,503
Nova Eye	43	37	40
Orthocell	293	199	208
Polynovo	936	584	694
Syntara	44	51	51
Telix	5,095	4,781	5,219
Second 20			
Actinogen	92	154	161
Alcidion	128	118	130
Amplia	80	67	69
Artrya	251	657	693
Atomo	15	15	16
Botanix	294	52	55
Curvebeam	47	9	11
Emvision	171	148	159
Impedimed	79	16	18
Imugene	82	42	35
Lumos	94	94	99
Micro-X	51	19	20
Optiscan	74	151	162
Paradigm	119	98	137
Prescient	43	89	69
Proteomics	52	24	25
Racura Oncology	208	382	418
Resonance	18	31	28
Saluda	89	112	117
Starpharma	52	316	343

* Biotech Daily editor, David Langsam, owns shares in 4D Medical, Acrux, Actinogen, Alcidion, Amplia, Clarity, Cochlear, EBR, Nanosonics, Neuren, Patrys, Percheron, Polynovo and Telix, as well as unlisted and non-biotech stocks.
Through Australian Ethical Superannuation he has an indirect interest in other companies: **https://www.australianethical.com.au/personal/ethical-investing/companies-we-invest-in/.** These holdings are liable to change.

Biotech Daily can be contacted at: PO Box 500, Flemington, Victoria, Australia, 3031
email: editor@biotechdaily.com.au; www.biotechdaily.com.au